卫光生物：拟签1.13亿元血液制品技术合作合同

Core Viewpoint - The company plans to sign a technical cooperation contract for blood products with a partner, involving a total fee of $16 million, equivalent to approximately 113 million RMB [1] Summary by Categories Contract Details - The contract involves the technical licensing and transfer of production technology for six types of blood products [1] - The licensed production technology can be utilized at four production bases within the specified region [1] Financial Impact - The total fee for the contract is $16 million, which is expected to positively impact the company's operating results [1] Approval and Risks - The transaction does not constitute a major asset restructuring and falls within the board's approval authority [1] - The execution of the contract may be influenced by factors such as personnel, facilities, and exchange rates [1]